Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Innovent Forms Three-Drug $391.5 Million Collaboration with Incyte

publication date: Dec 17, 2018

Suzhou Innovent formed a $391.5 million collaboration for China rights to three clinical-stage drug candidates developed by Incyte of Palo Alto, CA. Innovent will make a $40 upfront payment, then follow with a $20 million milestone payment when it files its first China IND. It will also be responsible for $331.5 million in development, regulatory and commercial milestones. For Innovent, the agreement is the first time the company has ventured outside of its primary focus on antibody candidates. It expects to file the first IND in 2019. More details....

Stock Symbols: (HK: 01801) (NSDQ: INCY)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.